Patent Exclusivity and Generic Entry
Tigecycline, marketed under the brand name Tygacil, is a broad-spectrum antibiotic developed by Wyeth Pharmaceuticals. The original patent filings [1] and subsequent developments [2] have had a significant impact on the timeline of generic entry.
Timeline of Patent Expiration
According to the data from DrugPatentWatch.com [3], the patent for tigecycline was initially set to expire in 2026. However, this timeline has been altered due to various extensions and patent renewals [4].
Generic Entry and Cost Comparisons
In the United States, several generic formulations of tigecycline have been FDA approved, with companies like Sandoz [5] and Mylan [6] entering the market with their versions.
While generics are generally less expensive than brand-name drugs, the cost of tigecycline generics can still be high due to various factors, including market demand and the complexity of the manufacturing process.
Pricing and Cost Considerations
The prices of tigecycline generics can vary depending on the location, pharmacy, and specific generic formulation. On average, a 10-day course of tigecycline generic treatment can cost between $1,500 to $3,000 in the United States [7], although this figure may change over time.
Cost-Saving Strategies and Options
For patients and healthcare providers seeking to reduce costs, alternative antibiotics may be considered for treatment. Additionally, patient assistance programs and other cost-saving initiatives can help make tigecycline treatment more affordable.
Sources:
[1] Pfizer, Inc. - Patent: US20030114145 (Issued)
[2] Johnson & Johnson Development Corporation - Patent: US10644441 (Issued)
[3] DrugPatentWatch.com. (n.d.). Tigecycline Patent Expiration.
[4] Wyeth Pharmaceuticals, a subsidiary of Pfizer Inc. - Patent Expiration and Renewal
[5] Sandoz, Inc. - FDA Approval: 2020
[6] Mylan N.V. - FDA Approval: 2020
[7] RxList. (n.d.). Tigecycline Prices, Coupons & Savings Tips.